Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05249114 · ClinicalTrials.gov registry record · Phase 1

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

A Phase 1 study of Neuroendocrine Tumors, sponsored by Providence Health & Services.

Active
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT05249114: Active Phase 1 study of Neuroendocrine Tumors, sponsored by Providence Health & Services.

NCT05249114 is a Phase 1 study of Neuroendocrine Tumors that is active but no longer recruiting, run by Providence Health & Services. The registered enrollment target is 6 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05249114, a Phase 1 study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Providence Health & Services.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.

Primary Outcome

The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib. Due to overlapping toxicities of cabozantinib and Lu-177 dotatate and to allow more incremental dose escalation of cabozantinib, alternating day dosing of 40mg/20mg and 60mg/40mg cohorts are incorporated into the schem

Conditions Studied

Neuroendocrine Tumors

Interventions

  • DRUG Cabozantinib
  • DRUG Lu-177

Study Locations (1)

Oregon

  • Providence Portland Cancer Institute - Franz Clinic - Portland

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-12-28
Est. Completion 2026-12
Phase Phase 1
Providence Health & Services

69 total trials

What the registry record for NCT05249114 still lists

NCT05249114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib is the first listed.

NCT05249114 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT05249114 about?

NCT05249114 is a clinical study titled "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors". The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.

What is the current status of trial NCT05249114?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-12-28. Estimated completion is 2026-12.

What conditions does trial NCT05249114 study?

This clinical trial studies the following conditions: Neuroendocrine Tumors.

What interventions are being tested in trial NCT05249114?

The interventions under investigation include: Cabozantinib (DRUG), Lu-177 (DRUG).

Who is sponsoring clinical trial NCT05249114?

This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05249114 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroendocrine Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05249114's enrollment target sits among peer trials

6 53rd of 52 the lowest of 52 other Neuroendocrine Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05249114, the US trial registry maintained by the National Library of Medicine. NCT05249114 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.